14th Annual Inflammatory Bowel Disease: The Art and Science in the Diagnosis and Treatment 2021

Gilead, Eli Lilly, Janssen, Takeda, Pharmaceuticals U.S.A., Inc., Bristol Myers Squibb
Meeting Description: 

We are pleased to announce that the Boston IBD 2021 meeting will be a hybrid meeting in 2021. We will hold an in-person meeting at the Aloft Hotel in Boston (following all Federal, State and local guidelines to do so safely) while broadcasting the meeting simultaneously on a virtual platform. Attendees have a choice to attend in person or virtually.

The goal of this hybrid conference is to initiate practice changes in gastroenterology practices in the diagnosis and management of patients with CD and UC so as to improve quality of life for these patients while prolonging clinical remission. This conference will provide support and enable participating clinicians to enhance their knowledge, competency, and performance in the areas of patient care, medical knowledge, and practice-based learning and improvement


At the conclusion of this activity, participants will be able to:

  1. Discuss emerging agents for IBD in terms of therapeutic target, safety and efficacy data, and place in therapy.
  2. Critically assess targets of mucosal healing used in treat-to-target strategies and the evidence that exists to support the use of these strategies in IBD patients.
  3. Differentiate the benefits and risks of biologic treatments in patients with IBD.
  4. Recognize the value and role of therapeutic drug monitoring.
  5. Explore the complex interplay of IBD and fertility concerns, pregnancy, and sexual function in women’s health.
  6. Evaluate key considerations and the latest emerging data for managing IBD in the era of COVID-19.
  7. Discuss issues related to men’s health in IBD.
  8. Interpret expert insights and emerging data for the novel treatment of C.diff recurrence with fecal microbiota transplantation.
  9. Promote and advocate for the patient’s role and voice in IBD shared decision-making to drive a more patient-oriented treatment approach.
  10. Evaluate the role of nutrition in the control of IBD and understand how diet affects microbiota.
  11. Review the role of diagnostic imaging and endoscopic biopsy in the diagnosis and monitoring of CD and UC.
  12. Identify the most current approaches to the management of postoperative recurrence in CD.
  13. Describe the medical and surgical approaches in patients with severe UC and pouchitis.
  14. Recognize the benefits of health maintenance (immunizations, psychosocial screening, and skeletal health assessment) in patients with CD and UC.
  15. Recognize how to effectively advocate for your patient when third party payors or specialty pharmacies deny care or access to needed treatments.
  16. Evaluate and treat extraintestinal manifestations in IBD
Physician MD
Nurse Practitioner
Physicians Assistant
Event Venue: 
United States
United States (Show on map)
Contact Name: 
Catherine Pagliaro
Email Address: 
Event Website: 
Start Date: 
9:00 AM
Finish Date: 
5:00 PM
Forgot/reset password
Sign in
Candidate registration
Sign in
Advertiser registration
Candidate registration
Advertiser registration
Candidate registration